Amgen Inc.
Clinical trials sponsored by Amgen Inc., explained in plain language.
A global biotechnology company developing therapies for cancer, kidney disease, and inflammation.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test two versions of cholesterol drug Results expected Sep 2026 (estimated)
- New obesity drug AMG 513 enters first human tests Results expected Sep 2026 (estimated)
- New drug aims to tame Sjögren's dryness and fatigue Results expected Oct 2026 (estimated)
- New combo therapy targets Hard-to-Treat cancers with genetic marker Results expected Oct 2026 (estimated)
- New drug combo targets rare lung tumor gene defect Results expected Oct 2026 (estimated)
-
Leukemia shot could replace long IV drips
Disease control Not yet recruitingThis study tests if a shot (subcutaneous) of the drug blinatumomab works as well as the standard IV drip for adults with a certain type of leukemia (Ph-negative B-cell ALL). About 560 people who are in remission after initial chemo will get either the shot or the IV, along with m…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can an unapproved device change how we manage this condition?
Disease control Not yet recruitingThis trial tests a medical device that has not been approved or cleared by the U.S. FDA. Researchers want to learn whether the device is safe and whether it can help people with a specific condition. Participants receive the device as part of the study, and the team monitors thei…
Phase 4 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug trial aims to tame rare inflammatory disease in kids
Disease control Not yet recruitingThis study tests a drug called inebilizumab in 15 children aged 2 to 17 who have IgG4-related disease, a rare condition that causes swelling and damage in organs. The drug is given through an IV and works by lowering certain immune cells to reduce inflammation. Researchers will c…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug aims to tame autoimmune hepatitis and cut steroid use
Disease control Not yet recruitingThis study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive e…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
One shot or two? scientists test how the body handles osteoporosis drug
Knowledge-focused Not yet recruitingResearchers are testing whether romosozumab, a drug used to treat osteoporosis, reaches the bloodstream the same way when given as one larger injection or two smaller injections under the skin. The study enrolls healthy adults aged 18 to 60. Blood samples will measure drug levels…
Phase 1 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC